1. Litwin MS, Lubeck DP, Henning JM, Carroll PR: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.J Urol 59:1988–1992, 1998.
2. Shimozuma K, Ohashi Y, Takeuchi gnA, Morita S, Ohsumi S, Sunada Y,Kuroi K, Makino H, Watanabe T, Hausheer FH; Validation of the Patient Neurotoxicity Questionnaire (PNQ) during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Proc. of 27th San Antonio Breast Cancer Symposium, 2004.
3. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Watanabe T, Hausheer FH: Assessment and quantification of tax-ane-induced neurotoxicity in a phase III randomized trial of patients with breast cancer (AC followed by PAC/DOC vs. PAC/DOC alone): N-SAS BC 02.J Clin Oncol 24:473s, 2006.
4. ‘Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQOL) measures in the evaluation of medicinal products’ European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use, Committee for Medical Products for Human Use (CHMP), London, 27 July 2005, http://www.emea.eu.int/pdfs/human/ewp/13939104en.pdf
5. ‘Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims (Draft guidance).’ U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologies Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH) Feb. 2006 http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf